Please login to the form below

Not currently logged in

Novo partners with NHS on diabetes care

Danish pharma company will work with King’s Health Partners in South London
Novo Nordisk headquarters

Novo Nordisk has teamed up with several NHS hospitals and a university in South London to provide an integrated care service for people with diabetes.

The company will work with King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts – collectively known as King's Health Partners – to develop a new model of specialist diabetes care in one of the most deprived parts of the UK.

Known as i3-diabetes, Novo said the five-year programme is a response to the changing role of diabetes care and will aim to integrate specialist services with community and primary care.

The programme, which is thought to be the first of its kind in the UK, has its foundations in a 2012 collaboration between King's Health and Novo that focused on understanding the needs of people with diabetes in South London and developing data around current diabetes care services.

Now the two organisations are ready to use this information in a practical way to develop two new approaches to change the way King's Health Partners delivers its care.

The first of these approaches covers improved care co-ordination, which will bring patients and specialists together to understand how healthcare staff can better support patients with complex needs and develop multiple interventions to improve patient experience.

The second approach aims to develop a more personalised approach to care, assessing the individual needs beyond the clinical diagnosis. This includes tailoring care based on a patient's psychosocial, physiological, medical and social needs.

Peter Meeus, Novo's managing director for the UK, told PMLiVE the collaboration was an example of a sustainable way to provide innovation and improvement in patient care as healthcare systems face financial challenges.

“Cost-containment in the NHS shouldn't be at the expense of patient care,” said Meeus. “There are different and new ways we can look at.”

He also explained that the company will be takeing a very hands-on role in the partnership, with both Novo and King's Health Partners contributing resources and respective expertise in diabetes to develop the approaches outlined in the programme.

The location was also important for Novo, with Meeus explaining that King's Health partners covered a diabetes population of 90,000 people covering wide variety of ethnic backgrounds, meaning relevant data samples could be collated.

The programme's potential goes beyond south London, however, and Meeus said he was keen to “spread best practice and export learnings” from the partnership to other parts of the UK as well as other countries.

Article by
Thomas Meek

30th January 2014

From: Marketing, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...